P/E ratio for Enanta Pharmaceuticals (ENTA)

P/E ratio history for Enanta Pharmaceuticals from 2013 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
AbbVie ABBV	48.3	-5,180.68%	🇺🇸 USA
Johnson & Johnson JNJ	10.3	-1,183.08%	🇺🇸 USA
Vertex Pharmaceuticals VRTX	31.1	-3,371.73%	🇺🇸 USA
Merck MRK	54.6	-5,838.71%	🇺🇸 USA
Bristol-Myers Squibb BMY	14.5	-1,627.04%	🇺🇸 USA
Novartis NVS	26.2	-2,860.34%	🇨🇭 Switzerland

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.